logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia.

    Article - En anglais

    The therapeutic options for patients with acute leukemia who relapse after the initial transplant include second bone marrow transplantation (2BMT) and conventional chemotherapy (CC).

    In this work, we conducted an analysis of published survival data and we evaluated the cost-effectiveness of 2BMT in comparison with CC.

    We retrieved survival information on 167 patients treated with 2BMT and 299 patients treated with CC.

    Survival figures were derived from individual patient data and were compared between 2BMT and CC.

    The mean lifetime survival (MLS) was estimated for each of the two patient cohorts using standard techniques of survival-curve extrapolation.

    The cost data of patients given 2BMT or CC were estimated from published data.

    Our analysis of individual survival data showed that 2BMT improved survival at levels of statistical significance (survival gain=19.6 months per patient).

    Using an incremental cost of $90 000 per patient, the cost-effectiveness ratio of 2BMT in comparison with CC was calculated as $52 215 discounted dollars per discounted life year gained.

    Our results indicate that, in patients with acute leukemia who relapse after their first transplant, 2BMT significantly prolongs survival in comparison with CC and seems to have an acceptable cost-effectiveness profile.

    Mots-clés Pascal : Leucémie lymphoblastique, Leucémie myéloblastique, Homogreffe, Greffe, Moelle osseuse, Traitement, Pronostic, Analyse coût efficacité, Economie santé, Homme, Aigu, Hémopathie maligne, Lymphoprolifératif syndrome, Seconde greffe

    Mots-clés Pascal anglais : Acute lymphocytic leukemia, Acute myelocytic leukemia, Homograft, Graft, Bone marrow, Treatment, Prognosis, Cost efficiency analysis, Health economy, Human, Acute, Malignant hemopathy, Lymphoproliferative syndrome, Second graft

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0201768

    Code Inist : 002B27D02. Création : 16/11/1999.